Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Co...
Journal Information
Vol. 42. Issue 8.
Pages 524-530 (October 2018)
Download PDF
More article options
Vol. 42. Issue 8.
Pages 524-530 (October 2018)
Original article
DOI: 10.1016/j.acuroe.2018.07.006
hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test®
Expresión de ARNm de hTERT en orina como herramienta diagnóstica útil en cáncer de vejiga. Comparación con citología y NMP22 BladderCheck Test®
J.A. March-Villalbaa, J. Panach-Navarretea,
Corresponding author

Corresponding author.
, M.J. Herrero-Cerverab, S. Aliño-Pellicerb, J.M. Martínez-Jabaloyasa
a Servicio de Urología, Hospital Clínico Universitario de Valencia, Facultat de Medicina i Odontologia, Universitat de València, Valencia, Spain
b Departamento de Farmacología, Facultat de Medicina i Odontologia, Universitat de València, Valencia, Spain
Article information
Full Text
Download PDF
Figures (2)
Tables (3)
Table 1. Comparison of hTERTN urine levels between different grades (WHO classification 1973 and 2004) and stage subtypes.
Table 2. Comparison of hTERTN urine levels between patients according to recurrence (4 years of follow-up). Mann–Whitney U-test.
Table 3. Diagnostic accuracy of cytology, NMP22 BladderCheck Test® and hTERTN urine levels. Positive predicitve value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (−LR).
Show moreShow less

To study the relationship between quantitative mRNA determination (hTERT) in patients with bladder tumor, history of bladder tumor, and in subjects without a history of this neoplasia.

Material and methods

A prospective randomized controlled study with 91 subjects included. The value of mRNA-hTERTN was determined in 63 patients with a history or suspicion of bladder tumor and in 28 controls. Urine samples were sent for evaluation of the mRNA level (hTERT), the cytological study and the NMP22 result.


Differences were observed in mean hTERTN levels in each of the groups: tumor presence 21.33±40.66, tumor history 2.16±2.67, controls 0.9±1.75 (p<0.001). In patients with tumor, there was no difference in mean hTERTN levels between the different grades and stages, although there was a tendency: low grade tumor 9.04±16.95, high grade 28.95±48.36 (p=0.069), stage Ta 10.33±19.39, T1 17.88±27.14, T2 54.8±74.05 (p=0.056). In addition, the sensitivity of hTERTN was superior to that of other test (76%), although specificity and positive and negative predictive values were better for cytology (94%, 88.4% and 72.3% respectively) and NMP22 (88%, 80.6% and 73.3% respectively).


hTERTN mRNA levels in urine were higher in patients with bladder tumors compared to patients with a history of bladder tumor and with negative cystoscopy, as well as in the control group. This determination showed a higher diagnostic yield compared with the detection of NMP22 and urinary cytology.

Bladder cancer
Diagnosis. Telomerase

El objetivo fue estudiar la relación entre la determinación cuantitativa de ARNm (hTERT) en pacientes con tumor vesical, antecedentes de tumor vesical y en sujetos sin antecedentes de esta neoplasia.

Material y métodos

Se trata de un estudio prospectivo, aleatorizado y controlado con 91 sujetos incluidos. El valor de ARNm-hTERTN se determinó en 63 pacientes con antecedentes o sospecha de tumor vesical y en 28 controles. Se enviaron muestras de orina para evaluar el nivel de ARNm (hTERT), el estudio citológico y el resultado de NMP22.


Se observaron diferencias en los niveles medios de hTERTN en cada uno de los grupos: presencia de tumor 21,33+/- 40,66, antecedente del tumor 2,16+/- 2,67, controles 0,9+/- 1, 75 (p<0,001). En pacientes con tumor, no hubo diferencias en los niveles medios de hTERTN entre los diferentes grados y estadios, aunque hubo una tendencia: tumor de bajo grado 9,04+/- 16,95, grado alto 28,95+/- 48,36 (p=0,069), estadio Ta 10,33+/- 19,39, T1 17,88+/- 27,14, T2 54,8+/- 74,05 (p=0,056). Además, la sensibilidad de hTERTN fue superior a la de otras pruebas (76%), aunque la especificidad y los valores predictivos positivos y negativos fueron mejores para la citología (94%, 88,4% y 72,3% respectivamente) y NMP22 (88%, 80,6% y 73,3% respectivamente).


Los niveles de mRNA de hTERTN en la orina fueron más altos en pacientes con tumores vesicales en comparación con pacientes con antecedentes de tumor de vejiga y con cistoscopia negativa, así como en el grupo de control. Esta determinación mostró un mayor rendimiento diagnóstico en comparación con la detección de NMP22 y citología urinaria.

Palabras clave:
Cáncer vesical


These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos